XtalPi Holdings (2228) Fundamentals 2026 — P/E 187.1x, Revenue Analysis | SniperIQ
XtalPi Holdings (2228) is a CN-listed Healthcare company in Medical - Healthcare Information Services with a market capitalization of HK
XtalPi Holdings (2228) has a market capitalization of approximately HK
XtalPi Holdings's trailing twelve-month P/E ratio is 187.1x, with a price-to-book (P/B) of 2.8x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
XtalPi Holdings runs a net profit margin of 15.4%, a gross margin of 69.8%, and an operating margin of -54.3%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
XtalPi Holdings reported revenue of ¥782M for fiscal year 2025, with net income of ¥121M and earnings per share (EPS) of 0.0319. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
XtalPi Holdings does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
XtalPi Holdings carries a debt-to-equity ratio of 0.05x and a current ratio of 14.77x, with a market beta of 1.32. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For XtalPi Holdings (2228) the key facts are: market cap HK
Get XtalPi Holdings's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.